Chiesi Farmaceutici S.p.a.

Merck Serono S. A.

Neumora Therapeutics, Inc.

Blackthorn Therapeutics, Inc.

Chris Knight

Ian Linney

Fabio Rancati

Wolfgang Schmidt

Andrea Rizzi

Robert M Jones

Mariangela Urbano

Laura Carzaniga

Gary Brandt

David Hardick

Jason Tierney

Anna Quattropani

Wesley Peter Blackaby

Charles Baker-Glenn

Agnes Bombrun

Chris Lock

Mark Stewart Chambers

Matthias Schwarz

Mark Stuart Chambers

Jerome Dorbais

Jerome Gonzalez

Christophe Cleva

Delphine Marin

Eric Sebille

Michael Barnes

Craig Rouse

Charles Baker Glenn

Agnès Bombrun

Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q, Q, Q, R, R, Rand X are as defined herein.

Vasopressin receptor antagonists and products and methods related thereto

Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R, R, R, Rand X are as defined herein.

Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.

Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.

The present invention provides compounds of Formula (I), as selective S1P1 inhibitors, as well as their use for treating multiple sclerosis and other diseases. 

5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(SIP)receptors

Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.

The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R, Rand Rare as defined in the description.

[object Object]

The invention relates to compounds of formula I: wherein R, R,R, R, X have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Growing community of inventors

Saffron Walden, United Kingdom

Chris Knight